On September 17, 2021, Gritstone bio, Inc. closed the transaction. The company received funding from 10 investors pursuant to exemption provided under Regulation D.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9618 USD | -0.09% | +19.32% | -52.85% |
04-30 | Gritstone Bio, Inc. Highlights the Durability and Potential Broad Utility of its Self-amplifying mRNA Vaccine at ESCMID Global 2024 | CI |
04-29 | Gritstone Bio, Inc. Announces Board Changes | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-52.85% | 103M | |
-3.89% | 88.14B | |
+1.45% | 40.51B | |
-14.43% | 31.67B | |
+51.20% | 24.62B | |
-14.85% | 15.65B | |
-13.87% | 12.07B | |
-7.87% | 11.97B | |
-39.40% | 11.61B | |
+5.62% | 8.81B |
- Stock Market
- Equities
- GRTS Stock
- News Gritstone bio, Inc.
- Gritstone bio, Inc. announced that it has received $55 million in funding from Frazier Management, L.L.C., Gilead Sciences, Inc., Redmile Group, LLC, Lighthouse Investment Partners, LLC and other investors